Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.
Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant gamma-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. gamma-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.
Von Hoff
D D
DD
University of Texas Health Science Center, San Antonio 78284-7884.
Fleming
T R
TR
Macdonald
J S
JS
Goodman
P J
PJ
Van Damme
J
J
Brown
T D
TD
O'Rourke
T
T
Feun
L G
LG
Keppen
M D
MD
D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D007371:Interferon-gamma